Different Antibiotic No Culture Eradicating (DANCE) strategy: An easy way to manage H. pylori eradication

被引:9
作者
Roccarina, Davide
Franceschi, Francesco
Zocco, Maria Assunta
Garcovich, Matteo
Gasbarrini, Giovanni [2 ]
Gasbarrini, Antonio [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Internal Med, I-00168 Rome, Italy
[2] Fdn Ric Med ONLUS, Bologna, Italy
关键词
Antibiotics; Eradication; Helicobacter pylori; MAASTRICHT-III CONSENSUS; HELICOBACTER-PYLORI; RESCUE THERAPY; TREATMENT FAILURE; TRIPLE THERAPY; QUADRUPLE THERAPY; SEQUENTIAL TREATMENT; INFECTED PATIENTS; REGIMENS; LEVOFLOXACIN;
D O I
10.1016/j.dld.2012.05.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Treatment of Helicobacter pylori infection is becoming a very relevant problem especially in industrialized Countries. Although different therapeutic regimens are currently available, treatment failure remains a growing problem in daily medical practice. Several factors could play a role in the eradication failure, but the most relevant are antibiotic resistance and patient's compliance. While Helicobacter pylori resistance to amoxicillin is rare, clarithromycin and metronidazole resistance varies significantly from close to zero up to 25%. However, metronidazole in vitro resistance exhibits a lower impact on eradication success because resistance in vitro does not reflect that in vivo. Specific guidelines have then been published, mostly based on antibiotic resistance among different geographic areas. Basically, first-line and second-line regimens have been well defined; concerning third-line treatment Maastricht III guidelines suggest to adopt a culture-based approach. Culture is, however, expensive, invasive and available only in few specialized centres. An alternative approach may be to use an empirical strategy, based on the avoidance of repeating similar eradicating schemes in the same patients during the course of different eradicating regimens. For this approach we propose the acronym DANCE (Different Antibiotic No Culture Eradicating) strategy. When correctly applied, this approach showed to reach successful eradication in up to 99.5% of Helicobacter pylori-positive patients. (c) 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:889 / 892
页数:4
相关论文
共 38 条
[1]   A 10-Day Levofloxacin-Based Therapy in Patients With Resistant Helicobacter pylori Infection: A Controlled Trial [J].
Bilardi, Claudio ;
Dulbecco, Pietro ;
Zentilin, Patrizia ;
Reglioni, Simona ;
Iiritano, Elena ;
Parodi, Andrea ;
Accornero, Laura ;
Savarino, Edoardo ;
Mansi, Carlo ;
Mamone, Mario ;
Vigneri, Sergio ;
Savarino, Vincenzo .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) :997-1002
[2]   Nitrofuran-based regimens for the eradication of Helicobacter pylori infection [J].
Buzas, Gyoergy M. ;
Jozan, Jolan .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (10) :1571-1581
[3]   Rifabutin-based Helicobacter pylori eradication 'rescue therapy' [J].
Canducci, F ;
Ojetti, V ;
Pola, P ;
Gasbarrini, G ;
Gasbarrini, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (01) :143-143
[4]   Cervia II working group report 2006:: Guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy [J].
Caselli, M. ;
Zullo, A. ;
Maconi, G. ;
Parente, F. ;
Alvisi, V. ;
Casetti, T. ;
Sorrentino, D. ;
Gasbarrini, G. .
DIGESTIVE AND LIVER DISEASE, 2007, 39 (08) :782-789
[5]  
Cudia B, 1997, GUT, V41, pA103
[6]   Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction [J].
De Francesco, V ;
Margiotta, M ;
Zullo, A ;
Hassan, C ;
Valle, ND ;
Burattini, O ;
Cea, U ;
Stoppino, G ;
Amoruso, A ;
Stella, F ;
Morini, S ;
Panella, C ;
Ierardi, E .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (03) :429-435
[7]   The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme:: a prospective, randomised study [J].
De Francesco, V ;
Zullo, A ;
Hassan, C ;
Della Valle, N ;
Pietrini, L ;
Minenna, MF ;
Winn, S ;
Monno, R ;
Stoppino, V ;
Morini, S ;
Panella, C ;
Ierardi, E .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (05) :322-326
[8]   Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure [J].
De Francesco, V ;
Zullo, A ;
Margiotta, M ;
Marangi, S ;
Burattini, O ;
Berloco, P ;
Russo, F ;
Barone, M ;
Di Leo, A ;
Minenna, MF ;
Stoppino, V ;
Morini, S ;
Panella, C ;
Francavilla, A ;
Ierardi, E .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (04) :407-414
[9]   Two new treatment regimens for Helicobacter pylori eradication:: a randomised study [J].
De Francesco, V ;
Zullo, A ;
Hassan, C ;
Faleo, D ;
Ierardi, E ;
Panella, C ;
Morini, S .
DIGESTIVE AND LIVER DISEASE, 2001, 33 (08) :676-679
[10]   'Rescue' therapies for the management of Helicobacter pylori infection [J].
Di Mario, Francesco ;
Cavallaro, Lucas G. ;
Scarpignato, Carmelo .
DIGESTIVE DISEASES, 2006, 24 (1-2) :113-130